Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

Gut

Volumn 49, Issue 3, 2001, Pages 436-440

  Walsh, K M ^b   Woodall, T ^b   Lamy, P ^c   Wight, D G D ^a   Bloor, S ^d   Alexander, G J M ^a,b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GILEAD SCIENCES   (United States)

^d Virco UK Ltd   (United Kingdom)

Author keywords

Adefovir dipivoxil; Fibrosing cholestatic hepatitis; Hepatitis B virus; Liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; AZATHIOPRINE; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PREDNISOLONE; TACROLIMUS; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; REMISSION; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OCCUPATIONAL DISEASES; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 0034862867     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.49.3.436     Document Type: Article

References (25)

1. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications
2. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
3. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
4. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
5. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
6. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
7. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis
8. Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture
9. Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy
10. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection
11. Attempted resolution of acute recurrent hepatitis B in a transplanted liver by the administration of ganciclovir
12. Treatment of fibrosing cholestatic hepatitis with lamivudine
13. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine
14. A novel selective broad-spectrum anti-DNA virus agent
15. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
16. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
17. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
18. "EUROHEP" consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis
19. Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation
20. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
21. Retransplantation in hepatitis B: A multicenter experience
22. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection
23. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo controlled phase II studies
24. High pretreatment serum hepatitis B titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
25. Adefovir depovixil for the treatment of hepatitis B mutants